Core B: Infectious Disease Assay Development

核心 B：传染病检测方法开发

• 批准号: 8812374
• 负责人: P Scott Hefty
• 金额: $ 21.17万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-15 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8812374
• 关键词: Animal Model; Area; Attention; Biochemical; Biological; Biological Assay; Biology; Biomedical Research; Cells; Chemicals; Communicable Diseases; Communication; Communities; Containment; Core Facility; Development; Disease; Ensure; Funding Opportunities; Genetic; Goals; Individual; Kansas; Lead; Molecular Probes; Organism; Outcome; Pathogenesis; Performance; Pharmaceutical Chemistry; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Scientist; Services; Source; Therapeutic; Training; United States National Institutes of Health; Universities; Validation; Virulence Factors; assay development; base; design; experience; hazard; high throughput screening; microbial; response; screening; small molecule libraries

SUMMARY The overall goal of the Infectious Disease Assay Development (IDAD) Core is provide expertise, facilities, services, and training in the area of HTS assay design, development, validation, small and large-scale screening for organism (cell) based or biochemical infectious disease targets. Assay development and performing high-throughput screening for infectious disease targets can be very similar to other biological and disease targets; however, there are often specific biological hazards associated with infectious disease targets that can require special consideration and conditions. This core will build upon current assets and expand the current capabilities by providing enabling expertise and dedicated attention of a core director and a technician to the community of infectious disease scientists and their biologically and disease relevant targets. Core staff will facilitate design, development, validation of assays suitable for automated high-throughput chemical screening. They will also facilitate small or large scale screening of compounds (at KU or from external sources). The expected outcomes of this core and associated efforts are well developed and validated assays suitable for automated large-scale screening that can be performed internally or externally. Hits generated through successful assay development and limited or large scale screening efforts will be directed into Core C and Core D to identify lead compounds for use as molecular probes and pre-therapeutics for infectious diseases. The expertise and resources will also enable investigators to develop competitive proposals in response to NIH funding opportunities.

概括 传染病分析开发（IDAD）核心的总体目标是提供专业知识，设施， HTS分析设计，开发，验证，小规模的服务和培训 筛查基于生物体（细胞）或生化传染病靶标。测定开发和 对传染病靶标进行高通量筛查可能与其他生物学和 疾病目标；但是，通常存在与传染病靶标相关的特定生物学危害 这可能需要特殊的考虑和条件。该核心将基于流动资产并扩展 通过提供核心主管和技术人员的专业知识和专门关注，通过提供当前功能 传染病科学家及其生物学和疾病相关的靶标的社区。核心人员 将有助于设计，开发，验证适用于自动高通量化学的测定 筛选。它们还将促进化合物的小或大规模筛选（在KU或外部 来源）。该核心和相关努力的预期结果得到了良好的发展和验证的测定 适用于可以在内部或外部进行的自动大规模筛选。生成的命中 通过成功的测定开发以及有限或大规模筛选工作将被引导到核心C中 和核心D以识别铅化合物作为分子探针和感染性治疗前的铅化合物 疾病。专业知识和资源还将使研究人员能够制定竞争性建议 对NIH资金机会的反应。